September 2015 The Committee for Melbourne has announced the members of the MELBOURNE 4.0 Steering Committee. The Steering Committee will drive the MELBOURNE 4.0 engagement process and ensure concrete policy initiatives are identified. Reflective of the Committee for…
September 2016 A new pathway for engagement with the Federal Government on issues concerning the sector is through the recently established Industry Growth Centres. Last week, BioMelbourne Network held a CEO lunch with Sue MacLeman, CEO MTPConnect as…
Melbourne-based health technology start-up company, MyGolgi, have won the 2016 Victorian State Government supported Innovation Showcase Scholarship. MyGolgi offer an easy-to-use wearable that provides consumers with continuous feedback for injury rehabilitation and prevention. The innovative device consists of…
If you’re reading this through the misery of a mid-winter flu, at least you’re better off than the poor Bendigo boy who found himself in World War I with a bullet wound in the arm, tuberculosis in the…
Every year millions of people die or become gravely ill from infectious diseases such as influenza, HIV, Chlamydia and Zika virus. Currently, 80 per cent of all tests for infectious diseases involve taking a patient sample and sending…
New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such…
Gordagen Pharmaceuticals, a private Australian company developing biopharmaceuticals and nutraceuticals based on the medicinal properties of tocotrienols, is pleased to announce it has received a Research and Development Tax Incentive Refund of AUD$1.3 million for the 2015/2016 financial…
Around the world 700,000 people die of drug resistant infections a year, and that figure could rise to 10 million a year by 2050. The resulting financial cost is predicted to reach $100 trillion USD. It’s a global problem…
Melbourne-based company, and BioMelbourne Network Member, AdAlta Limited has listed on the ASX. AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known…
A potent anti-cancer treatment co-developed and trialled in Melbourne has been granted approval for use in patients by the powerful US Food and Drug Administration (FDA). The announcement recognises that the drug, venetoclax, is a successful new therapy…
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. The unprecedented view of the protein doublecortin…
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. More than one in 10 stomach cancers…